Trevor Angell, MD

Associate Professor of Clinical Medicine

Associate Medical Director of Thyroid Center

Image of Trevor Angell, MD
Is this your profile? Click to edit

Overview

Trevor E Angell, MD is an Associate Professor of Clinical Medicine in the Department of Medicine’s division of endocrinology and diabetes at Keck School of Medicine of USC. Dr. Angell is board certified in internal medicine and diabetes, endocrinology and metabolism. His clinical and research interest is the diagnosis and treatment of thyroid diseases. He is recognized for clinical expertise in thyroid nodules, thyroid cancer, and thyroid disorders during pregnancy. He is nationally known for research into thyroid nodule evaluation and molecular testing of thyroid nodules. Dr. Angell has published articles in JAMA Surgery, Thyroid, the Journal of Clinical Endocrinology and Metabolism, and Current Opinion in Endocrinology and Diabetes, including original research and invited reviews. He has received funding for his research predicting thyroid cancer in patients with thyroid nodules from the Thyroid Cancer Survivors’ Association (American Thyroid Association Research Grant). He is on the editorial board of the top endocrinology journals, including Thyroid and the Journal of Clinical Endocrinology and Metabolism. He is currently a member of the American Thyroid Association Thyroid Nodule Guidelines Taskforce and a member of the International Thyroid Oncology Group. After finishing his clinical and research training at the Keck School of Medicine and the Los Angeles General Medical Center, Dr. Angell became an instructor in medicine at the Brigham and Women’s Hospital and Harvard Medical School, performing patient care, residents and fellow teaching, and research. Dr. Angell returned to USC and joined the faculty at the Keck School of Medicine in 2018.

Publications

  • Evolving trends in pediatric thyroid nodules and cancer management. Ann Pediatr Endocrinol Metab. 2026 Jun; 31(3):149-159.. View in PubMed
  • Impact of race/ethnicity and the presence of immune-related adverse events on outcomes for non-small cell lung cancer patients treated with immune checkpoint inhibitors. Ther Adv Med Oncol. 2026; 18:17588359261423890.. View in PubMed
  • Decreased risk of post-thyroidectomy hypocalcemia with history of GLP-1RA use. J Endocr Soc. 2026 Jan; 10(1):bvaf204.. View in PubMed
  • Consensus-based disease definitions for endocrine immune-related adverse events of immune checkpoint inhibitors. J Immunother Cancer. 2025 Oct 15; 13(10).. View in PubMed
  • Neighborhood deprivation and iodine levels influence air pollution effects on maternal thyroid function in early pregnancy. Environ Res. 2025 Jul 15; 277:121543.. View in PubMed
  • Polyfunctional T follicular helper cells drive checkpoint-inhibitor diabetes and are targeted by JAK inhibitor therapy. JCI Insight. 2025 Jul 08; 10(13).. View in PubMed
  • Impact of Modern Systemic Therapies on Survival in Patients with Anaplastic Thyroid Cancer: A Single-Center Retrospective Cohort Review. Drugs Real World Outcomes. 2025 Jun; 12(2):295-300.. View in PubMed
  • Response to Letter to the Editor From Luis Del Carpio-Orantes: [Impact of Surreptitious Glucocorticoids in Over-the-counter Arthritis Supplements]. J Endocr Soc. 2025 May; 9(5):bvaf045.. View in PubMed
  • Thyroid cancer. Semin Perinatol. 2025 Mar; 49(2):152042.. View in PubMed
  • Impact of Surreptitious Glucocorticoids in Over-the-Counter Arthritis Supplements. J Endocr Soc. 2025 Jan 06; 9(2):bvae227.. View in PubMed